BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 23378010)

  • 1. Evaluation of the QMS® Teicoplanin Immunoassay (ThermoFisher Scientific) on Cobas® 8000 System (Roche Diagnostics) and comparison to fluorescence polarization immunoassay for the determination of teicoplanin concentrations in human plasma.
    Dailly E; Fraissinet F; Deslandes G; Bouquié R; Jolliet P
    J Clin Lab Anal; 2013 Mar; 27(2):96-8. PubMed ID: 23378010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance of a fluorescence polarization immunoassay for teicoplanin in serum.
    Mastin SH; Buck RL; Mueggler PA
    Diagn Microbiol Infect Dis; 1993 Jan; 16(1):17-24. PubMed ID: 8425374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of a free phenytoin assay on Cobas c501 analyzer using calibrators from Cobas Integra free phenytoin assay by comparing its performance with fluorescence polarization immunoassay for free phenytoin on the TDx analyzer.
    Dasgupta A; Davis B; Chow L
    J Clin Lab Anal; 2013 Jan; 27(1):1-4. PubMed ID: 23325740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assay of teicoplanin in serum: comparison of high-performance liquid chromatography and fluorescence polarization immunoassay.
    McCann SJ; White LO; Keevil B
    J Antimicrob Chemother; 2002 Jul; 50(1):107-10. PubMed ID: 12096014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis using fluorescence polarization immunoassay for unbound teicoplanin concentration in serum.
    Urakami T; Maiguma T; Kaji H; Kondo S; Teshima D
    J Clin Pharm Ther; 2008 Aug; 33(4):357-63. PubMed ID: 18613853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantification of teicoplanin in plasma by LC-MS with online sample clean-up and comparison with QMS assay.
    Mueller DM; von Eckardstein A; Saleh L
    Clin Chem Lab Med; 2014 Jun; 52(6):879-87. PubMed ID: 24445242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical evaluation of teicoplanin fluorescence polarization immunoassay.
    Rybak MJ; Bailey EM; Reddy VN
    Antimicrob Agents Chemother; 1991 Aug; 35(8):1586-90. PubMed ID: 1834014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of fluorescence polarization immunoassay and high-performance liquid chromatography methods for assay of teicoplanin: can correlation be improved?
    Davani S; Bérard M; Royer B; Kantelip JP; Muret P
    Pathol Biol (Paris); 2004 Dec; 52(10):584-8. PubMed ID: 15596307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New modified fluorescence polarization immunoassay does not falsely elevate vancomycin concentrations in patients with end-stage renal disease.
    Smith PF; Petros WP; Soucie MP; Copeland KR
    Ther Drug Monit; 1998 Apr; 20(2):231-5. PubMed ID: 9558140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of a Methotrexate Chemiluminescent Microparticle Immunoassay:  Comparison to Fluorescence Polarization Immunoassay and Liquid Chromatography-Tandem Mass Spectrometry.
    Bouquié R; Grégoire M; Hernando H; Azoulay C; Dailly E; Monteil-Ganière C; Pineau A; Deslandes G; Jolliet P
    Am J Clin Pathol; 2016 Jul; 146(1):119-24. PubMed ID: 27357291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of blood sirolimus concentrations in liver and kidney transplant recipients using the Innofluor fluorescence polarization immunoassay: comparison with the microparticle enzyme immunoassay and high-performance liquid chromatography-ultraviolet method.
    Bouzas L; Hermida J; Tutor JC
    Ups J Med Sci; 2009; 114(1):55-61. PubMed ID: 19242874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between everolimus blood concentration assessed using the Innofluor Certican Fluorescence Polarization Immunoassay and the Architect i System sirolimus chemiluminescent microparticle immunoassay.
    Coentrão L; Carvalho C; Sampaio S; Oliveira JG; Pestana MI
    Transplant Proc; 2010 Jun; 42(5):1867-9. PubMed ID: 20620539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Establishment of norvancomycin fluorescence polarization immunoassay for therapeutic drug monitoring.
    Wu XJ; Zhang J; Yu JC; Cao GY; Shi YG; Zhang YY; Wang MG
    J Antibiot (Tokyo); 2012 Jan; 65(1):35-9. PubMed ID: 22045420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the Novel Methotrexate Architect Chemiluminescent Immunoassay: Clinical Impact on Pharmacokinetic Monitoring.
    Aumente MD; López-Santamaría J; Donoso-Rengifo MC; Reyes-Torres I; Montejano Hervás P
    Ther Drug Monit; 2017 Oct; 39(5):492-498. PubMed ID: 28682926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Innofluor fluorescence polarization immunoassay kits for the determination of serum concentrations of gentamicin, tobramycin, amikacin and vancomycin.lesassays@ukneqasaa.win-uk.net.
    White LO; Holt HA; Reeves DS; MacGowan AP
    J Antimicrob Chemother; 1997 Mar; 39(3):355-61. PubMed ID: 9096185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of QMS everolimus assay using Indiko analyzer: comparison with an ultra-performance liquid chromatography-tandem mass spectrometry method.
    Buthiau D; Bargnoux AS; Badiou S; Sutra T; Dupuy AM; Pageaux GP; Mourad G; Cristol JP
    Ther Drug Monit; 2015 Apr; 37(2):275-8. PubMed ID: 25254414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The quality of clinical serum teicoplanin assays: an experimental European EQA distribution.
    White LO; McMullin C; Davis AJ; MacGowan AP; Harding I; Reeves DS
    J Antimicrob Chemother; 1996 Oct; 38(4):701-6. PubMed ID: 8937964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of a new serum topiramate immunoassay to fluorescence polarization immunoassay.
    Snozek CL; Rollins LA; Peterson PW; Langman LJ
    Ther Drug Monit; 2010 Feb; 32(1):107-11. PubMed ID: 20010458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Teicoplanin measurement in patients with renal failure: comparison of fluorescence polarization immunoassay, microbiological assay, and high-performance liquid chromatographic assay.
    Awni WM; St Peter WL; Guay DR; Kenny MT; Matzke GR
    Ther Drug Monit; 1991 Nov; 13(6):511-7. PubMed ID: 1837630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Considerable lack of agreement between S-FPIA and EMIT cyclosporine assay in therapeutic drug monitoring, of heart transplant recipients.
    Regazzi MB; Molinaro M; Tinelli C; D'Eril GM; Goggi C; Campana C; Fiorito V; Moratti R; Viganò M
    Ther Drug Monit; 2000 Dec; 22(6):712-5. PubMed ID: 11128239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.